Please note: The information displayed on this page might be outdated.
Atomwise: Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNetĀ® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
Biotech Company
Based in...
US - Pacific
717 Market Street #800
San Francisco, CA 94102
United States

Company Participants at Winter Private Company Showcase

Abraham Heifets
Atomwise, Co-Founder & CEO
Dr. Abraham Heifets is a Co-Founder and serves as Chief Executive Officer at Atomwise. He is an expert in big data and high-performance computing. He serves as Board Member at X-37. After completing his B.Sc. and M.E in Computer Science at Cornell, Abraham worked on high-performance computing at IBM's T.J. Watson Research Center. As a doctoral candidate at the University of Toronto, he created SCRIPDB, one of the largest public databases of patented chemical structures, and LigAlign, a protein analysis tool used by researchers in 70 countries. He was also named a fellow of Massey College and the Ontario Brain Institute.
Steph Simmons
Atomwise, Head of Operations